What Suprecur 0.15% Treats: Main Uses and Benefits

Suprecur 0.15% (Buserelin) is a therapeutic agent used across several distinct medical disciplines where symptomatic conditions are driven by the body's natural sex hormones (estrogen and testosterone). The core therapeutic goal is to help manage conditions such as hormone-dependent prostate carcinoma and endometriosis.

The medication is used for managing conditions, including advanced prostatic carcinoma, endometriosis, uterine fibroids, and Central Precocious Puberty, and is applied as an adjunct in Assisted Reproductive Technology (ART) protocols.

“The treatment supports the patient during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms.”

In oncology, it is applied in addressing symptoms related to tumor activity, which provides supportive therapeutic benefit and may assist with symptom management. For gynecological conditions, it provides supportive relief that helps ease the overall symptom burden by alleviating chronic symptoms such as severe pelvic pain and heavy bleeding. In pediatric settings, a key therapeutic goal is the reversible suppression of premature sexual development, which assists with maintaining the conditions for the child's adult height potential and supports a more appropriate timeline for maturation.

Quick Fact: Relief for Hormone-Driven Pain
Relief Target	Symptoms related to physical discomfort associated with endometriosis and uterine fibroids.
Primary Benefit	Provides support that helps ease the overall symptom burden linked to estrogen dependency.
Use Context	Applied in scenarios where additional management of discomfort is required during short-term regimens.

Regulatory References

1. Health Canada Product Monograph

Who Can and Cannot Use Suprecur 0.15%

Population eligibility for Suprecur 0.15% (Buserelin nasal spray) is strictly defined by regulatory documents based on the patient's condition, age, and existing health status. The medicine is primarily approved for use in Adult Males with advanced hormone-dependent prostatic carcinoma and Adult Females for conditions like endometriosis and as part of Assisted Reproductive Technology (ART) protocols.

---

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used in the following populations:

• Patients with known hypersensitivity to Buserelin, other GnRH agonists, or product excipients.
• Pregnant or breastfeeding women; pregnancy must be excluded before starting therapy.
• Females with undiagnosed abnormal vaginal bleeding.
• Males whose prostatic carcinoma is not hormone-dependent or who have undergone bilateral orchiectomy.

---

Conditional Use and Restrictions

Use is restricted or requires special caution in several populations:

• Age: Use in females under 18 years of age for gynecological conditions is generally not established.
• Comorbidity: Patients with diabetes mellitus, hypertension, or a history of depression require careful and regular monitoring during treatment.
• Organ Function: Use with caution is advised for patients with existing hepatic (liver) or renal (kidney) function disturbances, as the drug's effect may be prolonged.

Interactions with other medicines and products

The interaction profile of Buserelin (Suprecur 0.15%) is primarily defined by documented pharmacodynamic effects on co-administered substances and additive risks related to its known hormonal action, as established in government regulatory documents.

Drug-Drug Interaction Restrictions

Classification	Interacting Product Category	Official Restriction Description
Contraindicated	Medicines known to prolong the QT interval (e.g., Class IA and Class III antiarrhythmics)	Co-administration is formally prohibited due to the potential for additive effects on cardiac repolarization, which may lead to serious heart rhythm issues.
Clinically Significant	Antidiabetic agents (e.g., certain drugs and insulins)	The therapeutic effect of these agents may be attenuated when used concurrently.
Functional Risk	Hormonal contraceptives	The contraceptive function of these products is officially described as reduced or non-existent during co-use.

Population-Specific Interaction Notes

Patients with known heart or blood vessel conditions, including pre-existing rhythm problems, are noted to have an increased risk of heart rhythm problems when receiving Buserelin. Additionally, long-term use of corticosteroids or anticonvulsants, as well as chronic alcohol abuse, are documented as factors that contribute to the risk of decreased bone mineral content.

How Suprecur 0.15% Works

Central Pituitary Receptor Down-Regulation

Buserelin functions as a high-affinity superagonist for the Gonadotropin-Releasing Hormone Receptor (GnRHR) on pituitary cells. Its continuous, non-pulsatile administration drives GnRHR desensitization and functional down-regulation via receptor internalization. This molecular action fundamentally alters the GnRHR signaling pathway. The sustained nature of the effect requires continuous receptor stimulation to maintain the suppressed state.

HPG Axis Interruption and Hormonal Suppression

The functional down-regulation of the GnRHRs reduces the pituitary gland's capacity to release its signaling hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This disruption of the central signaling of the Hypothalamic-Pituitary-Gonadal (HPG) Axis breaks the communication loop. The resulting absence of these key drivers causes the peripheral gonads to cease steroidogenesis, leading directly to the systemic physiological outcome of suppressing circulating Testosterone and Estradiol levels.

Mechanistic Constraints: The Initial Flare

A key mechanistic constraint is the "flare effect," where the initial activation of the GnRHRs causes a temporary surge of LH, FSH, and sex hormones before the down-regulation mechanism is fully established. Furthermore, the mechanism is limited to the HPG axis, meaning it does not suppress the minor amounts of sex hormones produced independently by the adrenal glands.

Administration Guidelines for Suprecur 0.15% Nasal Spray

Suprecur 0.15% (buserelin) is administered via the intranasal route using the provided nasal spray pump. The instructions for use emphasize a strict dosing schedule and specific procedural steps to ensure proper drug delivery and absorption.

Dosing and Frequency

For the adult and adolescent regimen in assisted reproduction protocols, the dose is generally two sprays into each nostril, four times daily. This results in a total daily dose of 1.2 mg of buserelin and must be consistently spaced throughout the day to maintain effective therapeutic levels.

Administration Scope	Detail
Route	Intranasal Spray
Dosing	Two sprays per nostril, four times a day (8 sprays total daily)
Frequency	Daily, at evenly spaced intervals
Age Group	Adult and adolescent

Procedural Steps

1. Preparation (First Use): The nasal pump must be primed before the first application by holding the bottle upright and pressing the pump 5 to 8 times until a fine, even spray is produced. This step is not repeated for subsequent daily uses.
2. Pre-Administration: Gently blow your nose to clear the nasal passages, as this is necessary for stable absorption of the medicine.
3. Administration: Insert the tip of the nebuliser into one nostril, keeping the head slightly bent over the bottle, and administer two sprays. Repeat the two-spray process in the other nostril.

Missed Dose and Special Conditions

If a dose is missed, patients should continue with the next scheduled dose at the regular time; a double dose must never be taken to compensate for the forgotten one. If using a nasal decongestant, wait at least 30 minutes after using Suprecur 0.15% before applying the decongestant to avoid interference with absorption. The residual spray should be discarded one month after the first use.

Research Evidence / Overview of Studies for Suprecur 0.15%

Evidence for Use in Endometriosis and Uterine Fibroids

Research exploring the use of Buserelin nasal spray for gynecological conditions includes Randomized Controlled Trials (RCTs) and comparative studies to examine how symptoms change in women of reproductive age. Study designs monitored patient-reported physical discomfort, objective disease measurements, and shifts in serum estradiol levels. Studies monitored the measurement of specific biomarker levels, such as low estradiol levels. Research frequently documents that the recurrence of symptoms is often observed after the medicine is discontinued, and some trials relied on modest sample sizes.

---

Evidence for Use in Advanced Prostatic Carcinoma

The medicine was studied for use in adult men with locally advanced or metastatic prostate cancer. This evidence is derived mainly from Phase II trials and comparative cohort studies. Research examined the reduction of serum testosterone to castration levels and tracked anti-tumor response patterns. Studies report the measurement of low serum testosterone levels within one month in most evaluable patients. Research describes patterns of absorption variability, which was associated with less complete hormonal suppression in some studies comparing the nasal spray to injectable forms.

---

Evidence for Use in Assisted Reproductive Technology (ART)

Buserelin nasal spray was evaluated in numerous RCTs and clinical protocol studies involving infertile women undergoing procedures like IVF. Outcomes monitored included the prevention of premature ovulation and successful down-regulation of pituitary hormone activity. Studies reported achieving the measured levels of pituitary activity and contributed to the evidence landscape for standardized fertility protocols. A key research limitation is that the measured patterns of the nasal spray are reported as dependent on factors that influence absorption.

---

What is Still Uncertain About Suprecur 0.15% Research

The available research evidence highlights several areas where certainty remains low. Research describes patterns of absorption variability due to the nature of the nasal spray formulation. In both the prostate cancer and Central Precocious Puberty populations, comparative evidence is lacking when assessing the nasal spray against the injectable depot forms of the same drug class using large-scale, high-quality trials. Furthermore, data for long-term outcomes following repeated or extended treatment courses remain insufficient.

Key Studies & References

1. Health Canada Product Monograph: SUPRECUR Nasal Spray Solution 0.15% (Buserelin Acetate)
2. Treatment of Central Precocious Puberty: An update on the GnRH agonist triptorelin

Common questions about Suprecur 0.15% (FAQ)

Q: Why is Suprecur 0.15% sometimes called Buserelin?

A: Suprecur is the brand name used for the medicine, and Buserelin is the name of the active chemical ingredient (Buserelin acetate). It is common in official documentation and clinical practice for the drug to be referred to interchangeably by the name of its active ingredient.

Q: Can Suprecur 0.15% affect my blood pressure?

A: According to official product information, an increase in blood pressure has been reported as a side effect of the medicine. Regulatory guidance indicates that patients with pre-existing high blood pressure require monitoring during treatment.

Q: Does long-term use of Suprecur 0.15% affect bone density or increase the risk of osteoporosis?

A: Official information recognizes that a decrease in bone mineral content is an effect linked to the duration of therapy, which can increase the risk of conditions like osteoporosis. To limit this effect, the recommended maximum duration for a course of treatment is documented as 6 months.

Q: Can a common cold or blocked nose make the Suprecur nasal spray less effective?

A: Official administration instructions advise clearing the nasal passages, such as by gently blowing the nose, before using the spray. This step is recommended to ensure stable absorption of the medicine. Conditions that may affect the nose's function could potentially impact the intended absorption.

Q: Why is Suprecur 0.15% sometimes given alongside other hormone treatments?

A: When treatment begins, the medicine can cause a temporary surge in hormones known as the 'flare effect,' which may temporarily worsen symptoms. In certain treatment protocols, such as for prostate cancer, other medication may be prescribed alongside Suprecur 0.15% to help manage and counteract this initial temporary effect.

Q: What is the difference in application technique between the injection and the nasal spray?

A: The Buserelin in Suprecur 0.15% is administered intranasally using a spray pump into the nostrils. Other Buserelin formulations, such as those used for different treatment phases or in certain male populations, are administered as a subcutaneous injection, meaning they are delivered under the skin.

Q: Is Suprecur 0.15% safe for people who have liver or kidney disease?

A: Regulatory documents indicate that patients with existing disturbances in liver (hepatic) or kidney (renal) function should use the medicine with caution. This is because the drug's effect may be prolonged in these cases, and the use of the medicine in these populations is associated with the requirement for careful monitoring.

Q: Is the nasal spray version of Suprecur 0.15% used for the same things as the injection?

A: Buserelin is available in both nasal spray and injection forms, which are used for different purposes or phases of treatment. The nasal spray, for example, is indicated for assisted reproduction technology (ART) protocols and endometriosis, while the injection form is indicated for conditions such as advanced prostatic carcinoma.

Q: How long does it usually take for Suprecur 0.15% to start working for fertility treatment?

A: According to clinical documentation, the planned therapeutic effect, which is the suppression of sex hormone secretion, is documented to begin within 1 to 2 weeks after starting the nasal spray.

Q: Are there any common over-the-counter medicines or supplements that interact with Suprecur 0.15%?

A: Official patient information advises caution regarding the co-use of over-the-counter (OTC) medicines, dietary supplements, and herbs. This warning is in place due to the potential for interactions that could diminish or enhance the medicinal effects of Suprecur 0.15%.

Q: Is it safe to drive or operate machinery while undergoing treatment with Suprecur 0.15%?

A: The medicine may cause certain neurological side effects, including dizziness, drowsiness, or blurred eyesight. If a person experiences these effects, official information indicates that caution must be taken, and tasks requiring concentration, such as driving or operating machinery, should be paused.

Q: Does Suprecur 0.15% impact the ability of men to have an erection?

A: As the drug works by suppressing sex hormone levels, side effects related to sexual function are documented. These include the reported side effect of erectile dysfunction (impotence).

Q: How quickly do side effects like hot flushes usually go away after treatment with Suprecur 0.15% ends?

A: Recovery of pituitary and gonadal function usually occurs within approximately 8 weeks after stopping treatment. However, documentation indicates that side effects like hot flushes may often stop a few months after the medicine is discontinued, but some people may continue to experience them.

Q: What kind of non-hormonal contraception should be used during treatment with Suprecur 0.15%?

A: Regulatory documents state that pregnancy must be excluded before and prevented during the use of this medicine. Official warnings advise using an effective method of birth control that is not an oral hormonal medicine, as hormonal contraceptives are noted to have reduced or non-existent function during co-use.

Q: Are there any restrictions on alcohol or caffeine intake while using Suprecur 0.15%?

A: Official safety information notes that chronic alcohol abuse is a documented risk factor that contributes to the decrease in bone mineral content associated with prolonged use of this medicine. No specific general restrictions regarding moderate caffeine consumption are specified in the regulatory documents.

Q: Is it normal to experience muscle or joint pain during Suprecur 0.15% treatment?

A: Yes, joint pain and bone pain are reported as side effects of the medicine. These effects are documented in the official regulatory product information.

Q: Are there any documented cases of Suprecur 0.15% being associated with changes in eyesight?

A: Reported side effects include blurred eyesight. Serious adverse reactions, though noted to be very rare, have included reports involving severe headache and eyesight problems.

Q: Can Suprecur 0.15% affect sleeping patterns or cause insomnia?

A: Yes, sleep disturbances are reported as a side effect of the medicine. If this effect persists or causes concern, it is relevant information for a healthcare professional.

Q: Why might a doctor prescribe a tablet along with Suprecur 0.15% at the start of treatment?

A: When treatment starts, a temporary surge in hormones known as the 'flare effect' can cause symptoms to temporarily worsen. In certain treatment settings, a second medication, often a tablet, may be prescribed to help control and manage this initial hormonal surge.

Q: Is there a link between Suprecur 0.15% and changes in cholesterol or lipid levels?

A: Studies have examined the effects of this drug on lipid (cholesterol) metabolism. The research indicates that changes in lipoprotein and cholesterol levels can be reported during the course of treatment.

Q: What is the typical time frame for the entire course of Suprecur 0.15% treatment?

A: The duration of treatment is decided by the doctor based on the condition being treated. However, due to the risk of decreased bone mineral content, the recommended maximum duration for a single course of treatment is documented as 6 months for certain indications.

Q: What are the signs of Ovarian Hyperstimulation Syndrome (OHSS) that are relevant to Suprecur 0.15% use?

A: OHSS is a serious complication associated with assisted reproduction protocols. Symptoms reported in official warnings can include significant abdominal swelling or pain, rapid weight gain, difficulty breathing, or passing less urine.

Q: Is it true that Suprecur 0.15% can contain benzyl alcohol?

A: Yes, the presence of benzyl alcohol as a component (excipient) is noted in some Buserelin formulations. This is included in official warnings, particularly concerning administration to infants and young children.

Q: Does Suprecur 0.15% affect the skin, such as causing acne or changes in hair thickness?

A: Acne is reported as a known side effect of the medicine. Additionally, because the drug affects sex hormone levels, studies have examined its use to address conditions involving changes in hair growth (hirsutism).

Official Storage and Disposal Instructions for Suprecur 0.15%

Suprecur 0.15% (Buserelin) Nasal Spray must be stored according to strict regulatory guidelines to maintain product stability.

Storage Requirement	Condition
Temperature	Do not store above 25 °C; Do not freeze
Light Protection	Store in the original outer carton
In-Use Stability	Must be used within five weeks after the first use

Handling and Safety: The medicine must be kept out of the sight and reach of children. The solution should not be used if it appears cloudy or discoloured.

Disposal: Unused or expired Suprecur must not be thrown away via household waste or wastewater. The product should be disposed of in accordance with local regulations, typically by returning it to a pharmacist for proper pharmaceutical waste handling.